low risk acute myeloid leukemia
Conditions
Interventions
IFN-a-2b group:Interferon-a-2b
Sponsors
People's Hospital, Institute of Hematology, Peking University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Low risk AML treated with standard induction chemotherapy; 3. CR1 was achieved and consolidation therapy was completed; 4. 4-6 courses of consolidation therapy was completed, including at least 2 medium dose cytarabine regimen; 5. 6 months after completion of consolidation treatment; 6. CR1 were maintained before receiving the study drug but MRD was positive; 7. The expected survival time is more than 3 months; 8. WHO PS score is 0-1; 9. Patients who are ineligibly for or refuse to accept allogeneic hematopoietic stem cell transplant; 10. Patients voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to drug ingredients, excipients;Allogeneic hematopoietic stem cell transplantation was performed; 2. Patients with acute promyelocytic leukemia;Intermediate- or high-risk AML; 3. Cardiac dysfunction or seriously impaired function of other important organ, serum ALT >= 2.5ULN, serum Cr >= 1.5ULN;Other malignant tumors; 4. Suffering from autoimmune diseases, epilepsy and functional impairment of the central nervous system; 5. Hematopoietic dysfunction; 6. Those who are expected to undergo a bone marrow transplant; 7. Pregnant and lactating women; 8. Having participated in other trials within the last 3 months; 9. Patients the researchers considered inappropriate for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRD negative conversion ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS (3 years);DFS(3 years);relapse rate; | — |
Countries
China
Contacts
Public ContactHao Jiang
Peking University People's Hospital
Outcome results
None listed